Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Video shows an RN assessing a patient wo has dyspnea and pain. She will use the symtom assessment acronym "NOPQRSTUV" to guide her assessment.
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; 1. Immunotherapy administration; 2. Immunotherapy; 3. Cancer immunotherapy; 4. CAR T-cell therapy; 5. Cytokine release syndrome; 6. Developming infrastructure; 7. Immunotherapy toxicities; 8. Checkpoint inhibitors; 9. Toxicity managment; 10.Oncolytic viruses
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
PART I: INTRODUCTION AND BACKGROUND; 1 INTRODUCTION; 2 CANNABIS; 3 CANNABIS: PREVALENCE OF USE, REGULATION, AND CURRENT POLICY LANDSCAPE; PART II: THERAPEUTIC EFFECTS; 4 THERAPEUTIC EFFECTS OF CANNABIS AND CANNABINOIDS; PART III: OTHER HEALTH EFFECTS; 5 CANCER; 7 RESPIRATORY DISEASE; 8 IMMUNITY; 9…
This publication represents the views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to humans, which met in Lyon, 24-31 May 2011
How to access the PDTM on VCH/PHC May 2008 version 1; Policies; Monographs; Appendices
c.1 BC Cancer Agency VAN Library | Available |